The formulation of a reasonable treatment for lung cancer is a comprehensive and systematic task. It should be based on the histopathology, clinical stage of lung cancer and the patient’s physical condition. Clinical staging is mainly based on the size of the primary focus, lymph node metastasis and whether there is distant metastasis, i.e. TNM staging. Since lung cancer can easily metastasize to the skull and bones insidiously, before clinical staging, cranial magnetic resonance or cranial enhanced CT examination and isotope bone scan (bone ECT) should be routinely performed. For small cell lung cancer, surgery is generally not an option, and chemotherapy or chemotherapy + radiotherapy is advocated first. It is also believed that if distant metastases are not yet found in small cell lung cancer, surgery can be performed after 3-4 courses of chemotherapy, followed by 2-3 courses of chemotherapy or local radiotherapy after surgery. In case of non-small cell lung cancer, the first thing to look at is the clinical stage: stage 0, stage I, stage II, stage IIIa. If the patient’s physical condition permits, surgery is preferred. The scope of surgery depends on the size of the lesion and the patient’s lung function. An additional 4-6 courses of adjuvant chemotherapy are required after surgery. If there are residual lesions or positive cancer cells at the cut edge after surgery, radiotherapy will be added. If the patient cannot tolerate surgery due to poor physical condition or does not want to undergo surgery, radiotherapy or radiotherapy+chemotherapy can be used. If the non-small cell lung cancer is stage IIIb or stage IV patients, chemotherapy and radiotherapy should be the main treatment. Targeted therapy can be considered for some patients. Targeted therapy is to target the specific (or relatively specific) molecules in tumor tissues or cells, and use molecular targeting drugs to specifically block the biological function of the target and selectively reverse the malignant biological behavior of tumor cells at the molecular level, so as to achieve the purpose of inhibiting tumor growth or even tumor regression. Epidermal growth factor (EGF) is the target of targeted therapy, including gefitinib and erlotinib. The treatment targeting tumor angiogenesis, such as Endo (recombinant human vascular endothelial inhibitor injection
), etc. Traditional Chinese medicine can be used as adjuvant treatment. In conclusion, the treatment of lung cancer is complicated, and the corresponding treatment methods should be selected according to the specific situation, and the comprehensive treatment is its fundamental.